Characteristics of WBN/Kob diabetic fatty rats supplemented with a fructose-rich diet as a metabolic syndrome model: response to a GLP-1 receptor agonist
-
Published:2018
Issue:10
Volume:80
Page:1515-1523
-
ISSN:0916-7250
-
Container-title:Journal of Veterinary Medical Science
-
language:en
-
Short-container-title:The Journal of Veterinary Medical Science
Author:
NAMEKAWA Junichi1, NEMOTO Sayaka1, SUNADA Gaku1, TAKANASHI Yuki1, FUJIO Sakurako1, SHIRAI Mitsuyuki1, ASAI Fumitoshi1
Affiliation:
1. Laboratory of Veterinary Pharmacology, School of Veterinary Medicine, Azabu University, Sagamihara, Kanagawa 252-5201, Japan
Publisher
Japanese Society of Veterinary Science
Subject
General Veterinary
Reference40 articles.
1. 1. Akimoto, T., Nakama, K., Katsuta, Y., Zhang, X. J., Ohsuga, M., Ishizaki, M., Sawai, N. and Ozawa, H. 2008. Characterization of a novel congenic strain of diabetic fatty (WBN/Kob-Lepr(fa)) rat. Biochem. Biophys. Res. Commun. 366: 556–562. 2. 2. Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N. and Tomlinson, J. W. 2016. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J. Hepatol. 64: 399–408. 3. 3. Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., Stocken, D., Gough, S. C., Tomlinson, J. W., Brown, R. M., Hübscher, S. G., Newsome, P. N. and LEAN trial team 2016. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387: 679–690. 4. 4. Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E., Niskanen, L., Rasmussen, M. F., Rissanen, A., Rössner, S., Savolainen, M. J., Van Gaal,, L. and NN8022-1807 Investigators 2012. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int. J. Obes. 36: 843–854. 5. 5. Buse, J. B., Drucker, D. J., Taylor, K. L., Kim, T., Walsh, B., Hu, H., Wilhelm, K., Trautmann, M., Shen, L. Z., Porter, L. E. andDURATION-1 Study Group 2010. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 33: 1255–1261.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|